HUTCHMED(HCM)
Search documents
HUTCHMED(HCM) - 2022 Q2 - Earnings Call Transcript
2022-08-03 15:53
HUTCHMED (China) Limited (NASDAQ:HCM) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Weiguo Su - Executive Director, Chief Executive Officer and Chief Scientific Officer Johnny Cheng - Executive Director and Chief Financial Officer Marek Kania - Executive Vice President, Managing Director and Chief Medical Officer, International Karen Atkin - Executive Vice President and Chief Operating Officer Hong Chen - Chief Commercial Officer of China, Senior Vice President and Chief Co ...
HUTCHMED(HCM) - 2022 Q2 - Quarterly Report
2022-07-31 16:00
Exhibit 99.1 HUTCHMED Reports 2022 Interim Results and Provides Business Updates Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA ® and ORPATHYS® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO® NSCLC1 patients with high MET 2levels and no prior chemotherapy Initiated six new trials thus far in 2022 with a further six starting, including with five new drug candidates FRESCO-2 Phase III, our first glob ...
HUTCHMED(HCM) - 2021 Q4 - Earnings Call Transcript
2022-03-04 01:07
HUTCHMED (China) Limited (NASDAQ:HCM) Q4 2021 Earnings Conference Call March 3, 2022 8:00 AM ET Company Participants Christian Hogg - Chief Executive Officer Hong Chen - Senior Vice President and Chief Commercial Officer, China Weiguo Su - Executive Director and Chief Scientific Officer Marek Kania - Executive Vice President, Managing Director and Chief Medical Officer, International Mark Lee - Senior Vice President, Corporate Finance & Development Johnny Cheng - Executive Director and Chief Financial Offic ...
HUTCHMED(HCM) - 2021 Q4 - Annual Report
2022-03-02 16:00
Exhibit 99.1 HUTCHMED Reports 2021 Full Year Results and Provides Business Updates Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE growth and the 2021 launches of SULANDA and ORPATHYS; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORPATHYS in lung cancer, kidney and gastric cancer during 2021; Broad late-stage development program – currently enrolling 13 registration studies on 6 assets – with enrollment on the 691 patient FRESCO-2 global Phase ...